Posted by: Puddy Dunne | December 9, 2014

Dead Doctors and Obamacare 2

Michael J, Rosenberg, Dead Doctors and Obamacare 2

cotomh370.jpg

Tales from the Research Triangle Park – Fiscal eBola  Vortex 3-9-6

Records link a doctor killed in a Gaithersburg plane crash to a 2010 crash in an approach to the same Montgomery County Airpark.

Gaithersburg (WUSA9) – A doctor killed in Monday’s Gaithersburg, Md. small jet crash is linked to a 2010 crash which was also heading to the Montgomery County Airpark.

The 66-year-old North Carolina doctor and businessman is identified in records as owning both crashed airplanes and may have been the pilot of at least one.

Authorities are investigating to determine who was at the controls in Monday’s crash.

FAA records don’t identify the pilot in the 2010 crash, but according to a 2010 Gazette article, the pilot of that crash was the doctor, Michael Rosenberg.

The 66 year old Rosenberg was the founder of a Durham North Carolina based pharmaceutical research company, which issued a statement Monday saying he was killed in the recent small jet crash.

“Everyone at Health Decisions is devastated,” said the company statement. “The thoughts of the management and employees of Health Decisions go out to Dr. Rosenberg’s family.”

Health Decisions Statement December 8

Records show the plane in the 2010 crash and the jet in Monday’s crash are both registered to Rosenberg.

WUSA9 footage from Montgomery County Airpark in March of 2010 shows about a hundred foot long line in the mud leading from the runway to the brush and trees where the pilot got out uninjured.

According to a FAA report on the 2010 crash, just before impact a stall alarm sounded on Rosenberg’s eight passenger turbo prop, a Socata TBM-700.

The pilot attempted to abort the landing and make another attempt the plane drifted, climbing about ten feet, then crashed nose down.

The FAA blamed the 2010 accident on the pilot failing to maintain aircraft control.

Injury averted in plane crash at Montgomery County Airpark

Wednesday, March 3, 2010
Injury averted in plane crash at Montgomery County Airpark
Pilot was trying to land turbo-prop Monday night

by Sebastian Montes | Staff Writer

A single-engine plane crashed Monday evening as it tried to land at the Montgomery County Airpark, careening into a nearby stand of trees and leaving the pilot with non-life-threatening injuries.

Firefighters responding to a call from the airport near Montgomery Village shortly after 5:30 p.m. Monday found the plane in the woods next the 4,200-foot runway, said Capt. Oscar Garcia, spokesman for Montgomery County Fire and Rescue Services. There was no evidence of fire or smoke, Garcia said.

The plane is a Socata TBM 700, a turbo-propeller plane that seats up to eight people. It is registered to Michael J. Rosenberg and Nova Aviation LLC, based in Port Orange, Fla., according to FAA records.

Rosenberg was flying in on a business trip from North Carolina, said Keith Miller, executive director of the Montgomery County Revenue Authority, which owns and operates the 50-year-old airport.

“The pilot is OK. He didn’t even go to the hospital,” Miller said Monday night.

The runway closed for more than an hour after the crash. Federal and county officials did not immediately know the cause.

“It looks like it came up just short of [the] runway,” Jim Peters, a spokesman for the Federal Aviation Administration, said Monday night.

FAA investigators arrived at the crash scene Tuesday morning.

The National Transportation Safety Board links 83 accidents to the airpark since 1964, the most recent in March 2009, when the pilot of a Cirrus SR22 became disoriented after take-off, deployed the plane’s parachute and narrowly missed dozens of homes as it came down on a street in the Flower Hill community.

Dr. Michael J Rosenberg

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
HEALTH DECISIONS CRO

Dr. Michael Rosenberg has been active in clinical research for more than 30 years, designing or conducting more than 300 studies worldwide in a range of therapeutic areas. Early in his career, he realized that excellence in clinical research requires elevating managerial standards to the same high level as scientific standards. He founded Health Decisions (www.HealthDec.com) in 1989 to develop a more efficient approach to managing clinical trials.

Under his guidance, Health Decisions has been recognized with many high-profile awards, including CIO’s Enterprise Value Award and the inclusion in Inc 500 and Technology Fast 500 fastest-growing private and technology-based companies, respectively. Ernst & Young also selected Dr. Rosenberg as Entrepreneur of the Year in Health Sciences.

Before founding Health Decisions, Dr. Rosenberg served as Executive Director and Chief Executive Officer of the American Social Health Organization, Director of the Reproductive Epidemiology Division of Family Health International, and Chief, Reproductive Health Activity, at Centers for Disease Control. He currently serves on the Leadership Council of the Harvard School of Public Health and as co-principal investigator of the Clinical and Statistical Coordinating Center for Contraceptive Research, National Institutes of Health. He has published more than 200 scientific articles, serves on the editorial boards of Current Drug Discovery and Contraceptive Technology Update, and is a reviewer for several journals.

Dr. Rosenberg also serves as Clinical Professor of Obstetrics and Gynecology at the University of North Carolina School of Medicine and Adjunct Professor of Epidemiology at the UNC School of Public Health. He is a Fellow of the American College of Physicians (Internal Medicine), the American College of Epidemiology, and the American College of Preventive Medicine. He completed his undergraduate and medical degrees at the University of California and received a Master’s Degree in Epidemiology and Biostatistics from the Harvard School of Public Health.

CRO Health Decisions, Evofem Lock Database in Largest Contraceptive Trial of Its Type

June 26, 2014

Durham, North Carolina. Health Decisions, the full-service CRO of choice for forward-looking biopharma and medical device companies, today announced database lock for Evofem’s phase 3 study of Amphora® nonhormonal contraceptive gel, the largest trial ever conducted of a nonhormonal contraceptive. Database lock marks an important milestone toward regulatory approval for Amphora, a potential alternative to Conceptrol®, the brand name of nonoxynol-9, the only spermicidal gel currently approved by the FDA.

“We are pleased to announce early database lock for this 3,389-subject global study of a potentially important new contraceptive alternative for women worldwide,” said Health Decisions CEO Michael Rosenberg, MD, MPH. “A combination of intensive study management based on streaming information and progressive subject-by-subject closeout enabled this important early step toward regulatory approval for a nonhormonal alternative to existing contraceptives.”

“We are excited to have reached this important milestone in the development of Amphora,” said Saundra Pelletier, CEO of Evofem Inc. “We really believe Amphora has tremendous potential to impact the lives of women, globally.”

Importance of Amphora’s Potential HIV-Preventative Effects If Confirmed
“We are excited about this Evofem development program both for now and future,” Rosenberg stated. “In the near term, Amphora, if approved as a contraceptive, will provide women around the world with greater contraceptive choice. It will have an important place as an inexpensive, easy-to-use, woman-controlled product used only when necessary and on demand.”
Looking at the longer term, Rosenberg said, “Although research will have to confirm this, Amphora may ultimately provide women for the first time with a single product that offers a combination of broadly effective contraception and HIV preventative effects.” Rosenberg stated that this unique combination could have important implications for global world health, in part because, according to the World Health Organization and FDA-mandated labeling requirements in effect since December 2007, the currently marketed nonoxynol-9 vaginal gel may actually increase the risk of acquisition of HIV in some circumstances.

Largest Contraceptive Trial of Its Type Enrolled 3x-4x Faster
Rosenberg, recently honored by the Association of Clinical Research Professionals with its 2014 Award for Innovation in Clinical Research, stated that Health Decisions’ innovative technology and processes enabled highly efficient study execution from startup through the most recent milestone, database lock.

“Our agile enrollment techniques enabled us to enroll almost 3,400 subjects three to four times faster than previous trials of similar products that enrolled less than half as many subjects. We enrolled 125 subjects per month compared with 38 subjects per month and 30 subjects per month for previous large studies of similar products. Our Agile Risk-Based Monitoring+ approach also enabled us to increase data quality simultaneously with reducing the percentage of data that was source verified.”

About Health Decisions
Health Decisions is the CRO of choice for forward-looking biopharma and medical device companies and a driving force in the modernization of clinical development. Health Decisions uses data-driven insight and agility to deliver clinical development success, reduce timelines and risk and increase quality and returns for biopharma and medical device companies worldwide. For 25 years and in more than 300 clinical trials involving tens of thousands of patients in many therapeutic areas, Health Decisions has improved the efficiency of clinical development through innovative methodology, processes and technology. Health Decisions’ clinical-development services have enabled biopharma and device companies to bring new products to market faster and at lower cost, thus providing the public with earlier access to improved treatments and diagnostics at more affordable prices. Health Decisions is headquartered in Durham, NC and operates on five continents.

About Evofem
Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with WomanCare Global, a nonprofit organization whose mission is to provide access to quality, affordable, women’s healthcare products through a sustainable supply chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, WomanCare Global provides sales, marketing and global distribution support to Evofem’s products.

Vaccines

Experience in Vaccine Clinical Trials

Health Decisions has conducted clinical trials of prophylactic and therapeutic vaccines for a variety of indications, including influenza, cytomegalovirus, and renal cell carcinoma. The methods that Health Decisions has developed for such studies are ideal for early phase studies of many types of prophylactic vaccines, including:

  • Cytomegalovirus
  • Hepatitis A, B and C
  • Herpes Zoster
  • HIV
  • HPV
  • Influenza, including TIV, H1N1
  • Meningococcal Meningitis
  • Pneumococcus
  • Rotavirus
  • Streptococcus
  • Varicella

Health Decisions Completes Enrollment In Phase II Flu Vaccine Trial

February 4, 2010 – Health Decisions, a full-service clinical research organization (CRO) specializing in high-efficiency adaptive solutions, has completed enrollment for a phase II universal flu vaccine study three weeks after the first site initiation visit and less than three months after the partnership was contracted…..

The vaccine’s developers chose to partner with Health Decisions for the CRO’s ability to meet two critical requirements that were vital to the study’s early success. First, all subjects had to be administered doses before the standard flu vaccine, to which the candidate was being compared, reached its expiration date. Missing this deadline would have meant losing months of progress waiting for a new batch to become available. In addition, reactogenicity data had to be captured, verified and made accessible to the sponsor immediately in order to closely monitor patients’ tolerability levels.

“The sponsor’s tight schedule and safety monitoring requirements presented a great opportunity for us to prove the capabilities of our Agile Clinical Development platform. We’re proud to support such an important medical breakthrough, and look forward to a bright future working with the sponsor to make vaccines more accessible to patients.”

Kelly Murray
Associate Director of Clinical Affairs
Health Decisions

Who or WHO is the partner, developer and sponsors

Contracts to Contractor(s) “HEALTH DECISIONS INC.”
(FY 2000-2012) FedSpending.org

# # #  other # # #

Latin, modification of Greek amphoreus, amphiphoreus, fromamphi- + phoreus bearer, from pherein to bear

Funding for the Development of Amphora

Evofem has received significant private funding for the development of Amphora.  In addition, public organizations and foundations invested substantial funds into the early development of the product, prior to its acquisition by Evofem.  Early funders of the product included CONRAD, the Centers for Disease Control and Prevention, and the National Institute of Health, among others.

CONRAD

Funding Partners

CONRAD Support Since 2008

CDC

USAID (Population and Contraception)

USAID (Microbicides)

NICHD

NIAID U19 Subawards and Other Microbicide Funding

Gates Foundation (Contraception)

Gates Foundation (Microbicides)

Concept Foundation

Other Private Foundation

1911 North Fort Myer Drive
Suite 900
Arlington, VA 22209

2013 Statement from the
Bellagio Group on LARCs

http://www.evofem.com/

Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date

About Evofem

Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with Woman Care Global, a nonprofit organization whose mission is to provide access to quality, affordable, women’s healthcare products through a sustainable value chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, Woman Care Global provides sales, marketing and global distribution support to Evofem’s products.

http://www.womancareglobal.org/wp-content/uploads/2013/09/FINAL-2013-Bellagio-Consensus-Statement-from-Addis-Meeting_12.18.13.pdf

 

# # #  other # # #

Research Triangle Park  – map and companies

# # #  other # # #

Woman Care Global – The Bellagio GroupThe Bellagio (Rockefeller) Center –

Group of Thirty – Medicago DARPA – coto2

As I have discussed in several posts, the everything vaccine will dominate and control billions of dollars while providing the sterilization (advanced nano-tech versions) through assorted pharma and M2e peptide adjuvants and synthetic protein cellular killers.  Here is a short list of the competitors, many at the Research Triangle

Acambis, VaxInnate, Merck, Vical and Dynavax Technologies Corporation, VaxInnate, Crucell NV, Inovio Pharmaceutical, Immune Targeting Systems, Israel’s BiondVax, Etubics Corp, FluGen, Gamma Vaccines and PT Bio Farma in Indonesia. The weather wars and Typhoons are involved in this as are Malaysia Flights MH17 and 370. There are no doubts this was a WELLSTONE hit assassination. Because the HEALTH DECISIONS and GOOGLEPLEX have not identified the Level PHASE II Vaccine sponsor and client, we can only guess what BIOTERRORIST group was involved or did it go higher to the Gang of 30, Gates and Rockefeller committee. Maybe someone will break further news. Below is a youtube by a gentlemen who also sees this was a hit or at least suspicious.

Tags: Fiscal eBola, Triangle Park, EMR, Bioterrorism, Agenda 21, Eugenics, Human Reproduction, Depopulation, Assassinations, Technocracy, Wellstoned, Dead Scientists, Covert Domestic Terrorism, NSA spying, Whistleblowers, Ft. Detrick, Research Triangle Park, USAMRIID, AIDS-HIV


Responses

  1. Jonathan Gruber Apology for Health Care Comments
    In his opening statement, MIT economist Jonathan Gruber apologizes for comments he made about the Affordable Care Act, calling them “glib, thoughtless, sometimes downright insulting,” and defends the federal health care law.

    http://www.c-span.org/video/?c4518208/jonathan-gruber-apology-health-care-comments

  2. related:

    Glen Thomas murdered Malaysia Flt MH-17
    https://cotocrew.wordpress.com/2014/10/22/zmapping-the-new-world-order/

    6 AIDS Experts Killed in Plane Crash
    http://www.slate.com/articles/health_and_science/science/2014/07/aids_researchers_on_mh17_missile_strike_killed_scientists_and_advocates.html

    Italian publication claims top Ebola expert murdered on flight MH17 as part of an elaborate cover-up https://www.intellihub.com/italian-publication-claims-top-ebola-expert-murdered-flight-mh17-part-elaborate-cover/

    Ebola kills 5 Sierra Leone researchers before their study on outbreak is published
    http://www.nydailynews.com/life-style/health/ebola-kills-5-researchers-outbreak-study-published-article-1.1922329

    Dead Scientists 2004-2014 Steve Quayle
    http://www.stevequayle.com/index.php?s=146

  3. Merck to take on superbugs with Cubist Pharma buy
    http://www.reuters.com/article/2014/12/09/us-cubist-pharma-m-a-merck-idUSKBN0JM19X20141209
    Merck to take on superbugs with Cubist Pharma buy

    (Reuters) – Merck & Co Inc (MRK.N) said it would buy Cubist Pharmaceuticals Inc (CBST.O) for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.

  4. December 8, 2014
    Durham, North Carolina.

    Health Decisions confirms with deep regret and great sadness that founder and CEO Michael Rosenberg, MD, MPH, died at approximately 11:00 a.m. December 8, 2014 in a private plane crash near Montgomery County Airpark in Gaithersburg, MD, a Washington DC suburb. “Everyone at Health Decisions is devastated by the loss of our friend and colleague Michael Rosenberg,” stated Health Decisions Vice President, Clinical Affairs Patrick Phillips, D Phil.

    “The thoughts of the management and employees of Health Decisions go out to Dr. Rosenberg’s family as well as to the families of the other passengers. “ “We can best honor Michael by carrying on and realizing his vision of a more efficient approach to clinical development,” Dr. Phillips stated. “We are committed to that goal.” Dr. Phillips stated that the Health Decisions Executive Team would announce succession plans at an appropriate time. No changes are anticipated in the company’s day-to-day business activities. Dr. Rosenberg founded Health Decisions, a leading Clinical Research Organization, in 1989 with the conviction that the development of new medicines and medical devices could and should be more efficient. Dr. Rosenberg’s focus on improving the efficiency of clinical development never wavered. The Association of Clinical Research Professionals recognized Dr. Rosenberg’s contributions with the 2014 Innovation in Clinical Research Award. Also in 2014,

    The Triangle Business Journal honored Dr. Rosenberg with its Life Sciences CEO of the Year Award. In addition to serving as Health Decisions’ CEO, Dr. Rosenberg was an award-winning author. His book, The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Research (Wiley 2010) received theJournal for Clinical StudiesJCS Library Award and was selected for the First Clinical Research Bookshelf by The Journal of Clinical Research Best Practices
    ))))))))))))))))))))))))))))))))))))))))))))))

    Seems very odd that HDI did not know this?

    Rosenberg’s two passengers were identified Tuesday as David Hartman, 52, vice president of clinical pharmacology, pharmacokinetics and nonclinical development at Nuventra Inc., a Durham-based clinical pharmacology consulting firm, and Chiji Ogbuka, 31, of Raleigh, a regulatory affairs manager with Health Decisions.
    Read more at http://www.wral.com/ntsb-plane-pitched-up-down-before-fatal-maryland-crash/14260309/#B0aHIY3e8b2xre6U.99

  5. David Hartman, 52, vice president of clinical pharmacology, pharmacokinetics and nonclinical development at Nuventra Inc.

    http://www.nuventra.com/nuventra/what-nuventra-does/

    Nuventra Pharma Sciences, a specialty pharmaceutical consulting firm, has quickly become the industry’s go-to resource for clinical pharmacology, pharmacokinetics (PK), pharmacodynamics (PD), PK/PD analysis, population PK (popPK) and modeling.

    What is clinical pharmacology, pharmacokinetics (PK) and pharmacodynamics (PD)?

    Clinical Pharmacology (ClinPharm) is the study and use of drugs in humans – such as how drugs affect the body (PK) and how the body affects drugs (PD). Pharmacokinetics describes each drug’s:

    absorption – how drugs get in the body (e.g. absorption into the blood after oral dosing)
    distribution – how drugs get around the body (e.g. distribution to different tissues in the body)
    metabolism – how drugs get broken down by the body
    excretion – how drugs get out of the body (e.g. excretion in urine)
    PK/PD Analysis – What Nuventra does?
    What is a PK/PD analysis?

    Clinical pharmacology investigations involve enrolling subjects (healthy volunteers or patients with disease) into a clinical study and having them take a test compound or study drug. Blood or other human fluids (e.g., urine, saliva, spinal fluid, etc.) are collected from the study subjects at specific timepoints after dosing. For example, a subject might take study drug at time zero and have blood collected at 1, 2, 3, 4, 8, 12, and 24 hours after dosing for PK analysis. These samples are sent to a bioanalytical laboratory to measure the concentration of drug in each sample.

    David Hartman received his PhD in medicinal chemistry and pharmacognosy at The Ohio State University in 1990 and completed a postdoctoral fellowship in molecular biology/virology at the University of Alabama at Birmingham in 1991. Dr. Hartman began his pharmaceutical career at Ricerca Biosciences where he held positions of increasing responsibility in the areas of drug metabolism and pharmacokinetics. He was eventually promoted to be the technical and administrative head for a team of scientists performing pharmacology, in vitro and in vivo DMPK studies for both Ricerca clients and internal discovery programs. Prior to joining Nuventra David was responsible for a team of preclinical consultants at Fulcrum Pharma Developments, later known as Aptiv Solutions, while also serving as the technical lead in various areas of drug development with primary emphasis in nonclinical and clinical PK, drug metabolism and pharmacology. He has a broad range of therapeutic area and regulatory experience having authored over 35 regulatory documents and participated in multiple regulatory meetings from preIND to preNDA.

  6. Missing Gaithersburg NIH scientist found dead in Alleghany County, Md.

    Read more: http://www.wjla.com/articles/2014/09/missing-gaithersburg-nih-scientist-found-dead-in-alleghany-county-106784.html#ixzz3LdkHxw69
    Follow us: @ABC7News on Twitter | WJLATV on Facebook

    No further autopsy info.


Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: